Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Más filtros

Bases de datos
Tipo de estudio
Tipo del documento
País de afiliación
Intervalo de año de publicación
1.
Ther Drug Monit ; 45(6): 711-713, 2023 12 01.
Artículo en Inglés | MEDLINE | ID: mdl-37448154

RESUMEN

ABSTRACT: Ceftazidime-avibactam (CTZ-AVM) is a novel cephalosporin/beta-lactamase inhibitor with broad-spectrum activity against multidrug-resistant Pseudomonas aeruginosa . Ceftazidime-induced neurotoxicity is a well-described adverse effect, particularly in patients with renal insufficiency. However, appropriate dosing of ceftazidime-avibactam in patients undergoing renal replacement therapy (RRT) is sparsely investigated, and therapeutic drug monitoring to guide dosing remains lacking. Furthermore, when dose adjustment for impaired renal function is based on CTZ-AVM product information, inferior cure rates have been obtained compared with those with the standard therapy for intra-abdominal infections. Maintaining an effective dose while avoiding toxicity in these patients is challenging. Here, the authors describe the case of a critically ill patient, undergoing 2 modalities of RRT, who developed ceftazidime-induced neurotoxicity as confirmed using ceftazidime therapeutic drug monitoring. This case illustrates a therapeutic drug monitoring-based approach for guiding ceftazidime-avibactam dosing in this context and in diagnosing the cause of neurological symptoms and signs.


Asunto(s)
Terapia de Reemplazo Renal Continuo , Rondas de Enseñanza , Humanos , Antibacterianos/efectos adversos , Ceftazidima/uso terapéutico , Combinación de Medicamentos , Monitoreo de Drogas , Pruebas de Sensibilidad Microbiana
2.
Neural Plast ; 2019: 7067592, 2019.
Artículo en Inglés | MEDLINE | ID: mdl-31065259

RESUMEN

Aging is a physiological process accompanied by cognitive decline, principally in memory and executive functions. Alterations in the connectivity of the default mode network (DMN) have been found to participate in cognitive decline, as well as in several neurocognitive disorders. The DMN has antisynchronic activity with attentional networks (task-positive networks (TPN)), which are critical to executive function and memory. Findings pointing to the regulation of the DMN via activation of TPN suggest that it can be used as a strategy for neuroprotection. Meditation is a noninvasive and nonpharmacological technique proven to increase meta-awareness, a cognitive ability which involves the control of both networks. In this review, we discuss the possibility of facilitating healthy aging through the regulation of networks through meditation. We propose that by practicing specific types of meditation, cognitive decline could be slowed, promoting a healthy lifestyle, which may enhance the quality of life for the elderly.


Asunto(s)
Encéfalo/fisiología , Envejecimiento Saludable/fisiología , Envejecimiento Saludable/psicología , Meditación , Procesos Psicoterapéuticos , Atención/fisiología , Disfunción Cognitiva/prevención & control , Humanos , Metacognición , Atención Plena , Vías Nerviosas/fisiología
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA